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Abstract
Objective: Bilateral lung volume reduction surgery (LVRS) has emerged as a palliative treatment option in patients with severe
pulmonary emphysema. However, it is not known if a sustained functional improvement can be obtained using an unilateral approach.
Methods: We hypothesized that a palliative effect can also be obtained by unilateral LVRS and prospectively assessed lung function,
walking distance, and dyspnea before and 3, 6, 12, 18, 24 and 36 months after unilateral LVRS. Results: Twenty-eight patients were operated
by the use of video-assisted thoracoscopic surgery (VATS) with a mean follow-up of 16.5 months (range 3–36 months). Forced expiratory
volume in 1 s (FEV1) was significantly improved up to 3 months (1007 ^ 432 compared to 1184 ^ 499 ml, P , 0:001), residual volume up
to 24 months (4154 ^ 1126 compared to 3390 ^ 914 ml, P , 0:01), dyspnea up to 12 months (modified Borg dyspnea scale 6:6 ^ 1:8
compared to 3:9 ^ 1:8, P ¼ 0:01) and walking distance up to 24 months (343 ^ 107 compared to 467 ^ 77 m, P , 0:05) after unilateral
LVRS compared to preoperative values. Overall, 25 of 28 patients reported a subjective benefit after unilateral LVRS. There was no 30-day
mortality. Only two patients required surgery on the contralateral side after 4.5 and 6 months, respectively, both suffering from a-1-
antitrypsin deficiency. Conclusions: Unilateral LVRS by the use of VATS results in a sustained beneficial effect, improving walking
distance and dyspnea for up to 24 months in patients with severe emphysema. The preservation of the contralateral side for future
intervention if required renders unilateral LVRS an attractive concept in this difficult palliative situation. q 2001 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Lung volume reduction surgery (LVRS) has emerged as a
promising option for palliation of selected patients with
severe, disabling emphysema. Several studies have shown
significant short- and mid-term improvements of dyspnea,
lung function, exercise capacity and quality of life after
LVRS [1–3]. A bilateral operation is the method of choice
in most centers, since the functional short-term results are
usually better compared to the unilateral procedure [4–6].
However, the reported results indicate that the pulmonary
function declines after LVRS [7,8]. Therefore, patients
might require further palliative procedures if lung function
and quality of life gradually worsen after the first interven-
tion.
A recent editorial emphasized the question about how
much lung tissue has to be removed to get optimal long-
term results [9]. We therefore established a protocol with the
possibility of a two-step procedure: we hypothesised that the
unilateral procedure is adequate to improve dyspnea and
exercise capacity, therefore fulfilling two important goals
of the palliative intervention. If lung function, dyspnea
and exercise capacity deteriorates over time to preoperative
levels, LVRS will be repeated on the contralateral side.
Since there are no prospective data on the long-term func-
tional outcome of patients undergoing unilateral LVRS, nor
the number of patients who would require a second inter-
vention on the contralateral side, we have prospectively
assessed dyspnea, lung function, and walking distance
before and after unilateral LVRS. To this end, all patients
referred to our institution and qualifying for LVRS were
operated unilaterally since 1996.
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2. Material and methods
2.1. Patient selection
Since March 1996, all patients with severe diffuse
emphysema qualifying for LVRS according to the published
guidelines [10] underwent unilateral LVRS after informed
consent. Inclusion criteria consisted of severe dyspnea at
rest or at minimal physical activity, forced expiratory
volume in 1 s (FEV1) ,35% of the predicted value and
severe hyperinflation with a residual volume (RV)
.200%, without improvement after optimal medical ther-
apy (including systemic corticosteroids), chest physiother-
apy and exercise training. Diffuse emphysema was
documented in all patients with high-resolution computer
tomography and ventilation/perfusion scintigraphy. Patients
with bullous disease without emphysema were excluded.
Exclusion criteria were age .75 years, a mean pulmonary
arterial pressure .35 mmHg determined by right-heart
catheterisation, active smoking, a PaCO2 .7.3 kPa, FEV1
,10% of the predicted value, signs for chronic productive
bronchitis or evidence of coronary heart disease based on
patient history and electrocardiogram. Before LVRS, all
patients underwent pulmonary rehabilitation for 3 weeks
without satisfying benefit.
2.2. Preoperative assessment
Preoperative evaluation included a patient history and
clinical examination. Patients were asked to classify their
degree of dyspnea according to the ATS shortness of breath
dyspnea scale (ranging from 0 to 4, meaning 0 without any
dyspnea and 4 with severe dyspnea at rest) and the modified
Borg dyspnea scale (ranging from 0 to 10, 10 with severe
dyspnea at rest). In addition, standard pulmonary function
test, body plethysmography, measurements of CO diffusion
capacity, 6-min walking test, chest X-ray, high-resolution
computed tomography, ventilation/perfusion scintigraphy
and right heart catheterisation were performed in each
patient. Left heart catheterisation was done if coronary
artery disease was suspected based on the patients history
and the ECG.
2.3. Operative approach and technique
All patients were operated unilaterally. The side with the
more heterogeneous pattern of emphysema was chosen
based on ventilation-perfusion scintigraphy and high-reso-
lution computed tomography. Patients underwent video-
assisted thoracoscopic surgery (VATS) using double-
lumen intubation and continuous thoracic peridural analge-
sia. Typically, 20–30% of the lung were resected by use of
an Endo-GIA stapler without buttressing the stapled resec-
tion line.
2.4. Follow-up and re-evaluation for LVRS on the
contralateral side
Follow-up examinations included dyspnea grading,
pulmonary function tests and 6-min walking test at 3, 6,
12, 18, 24 and 36 months after LVRS. LVRS on the contral-
ateral side was considered in patients with dyspnea and
exercise intolerance comparable to preoperative levels in
absence of exclusion criteria as mentioned above.
2.5. Statistics
Data are expressed as mean ^ standard deviation (SD).
Data of lung function testing, blood gas analysis and walk-
ing test were analysed using a linear mixed model with the
SAS procedure ‘mixed’ (SAS Institute Inc., NC USA;
Version 6.12). P-values were adjusted by the Dunnett–
Hsu-correction for multiple comparisons with one control.
Data regarding degree of dyspnea according to the ATS
shortness of breath scale and the modified Borg dyspnea
scale were analysed by use of the Wilcoxon signed-rank
test and Bonferroni-adjustment. Pre- and postoperative ster-
oid dependency was compared by use of the paired
Wilcoxon signed-rank test. A two-sided hypothesis was
used and a P-value of less than 0.05 was considered statis-
tically significant. All data were analysed by D. Dietrich,
Institute of Mathematical Statistics, University of Bern,
Switzerland.
3. Results
Twenty-eight patients (three women and 25 men) under-
went unilateral LVRS between March 1996 and October
1999. The mean age was 62.5 years, ranging from 51 to
75 years. Twenty-six patients had emphysema due to smok-
ing. Two patients were included with a-1-antitrypsin defi-
ciency, one with a homozygote and one with a heterozygote
phenotype. According to the emphysema morphology clas-
sification [11], all patients had moderate to marked hetero-
geneous emphysema. Twelve patients were operated on the
right upper lobe, eight on the left upper lobe, one on the
right lower lobe and five patients on the left lower lobe. One
patient underwent resection on the left upper and the left
lower lobe, one on the right upper and lower lobe.
All patients were extubated immediately after surgery.
No re-intubation, ICU stay for more than 2 days or tracheot-
omy were necessary. The mean duration of hospital stay was
29.9 days, ranging from 14 to 71 days.
There was no 30-day postoperative mortality. Morbidity
consisted of persistent air leaks .7 days in six patients
(21%), pneumonia in five (18%), and iliofemoral venous
thrombosis in one patient. One patient developed a
bronchopleural fistula 3 months after the operation.
Follow-up ranged from 3 to 36 months (mean follow-up
16.5 months). One year follow-up data were available in 17
patients, 2 years data in nine, and 3 years data in seven.
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Three patients were lost during follow-up due to moving
(n ¼ 1, 6 months) or unwillingness to further participate
(n ¼ 2, 12 months). Four patients (14%) died during the
observation period, one from chronic pulmonary infection
at 3 months, one from perforated sigma diverticulitis at 6
months, one from right heart failure at 12 months and one
from a bronchopleural fistula of the ipsilateral lung 16
months after LVRS.
Pulmonary function testing and subjective assessment
revealed a significant increase of FEV1 up to 3 months
(1007 ^ 432 compared to 1184 ^ 499 ml, P , 0:001), a
significant decrease of the RV up to 24 months
(4154 ^ 1126 compared to 3390 ^ 914 ml, P , 0:01),
and a significant decrease of dyspnea up to 12 months
(modified Borg dyspnea scale 6:6 ^ 1:8 compared to
3:9 ^ 1:8, P ¼ 0:01) after unilateral LVRS, as compared
to preoperative values (Figs. 1–3). No significant differences
were found between preoperative and postoperative values
regarding DLCO, PaO2 and PaCO2.
The 6-min walking distance increased significantly up to
24 months after unilateral LVRS (343 ^ 107 compared to
467 ^ 77 m, P , 0:05) (Fig. 4). Twenty-two patients
required daily steroid medication before compared to nine
patients after LVRS. The mean dose of steroid was 11:8 ^
6:4 mg prednisone equivalent per day before and 2:9 ^ 5:1
mg after LVRS at discharge (P ¼ 0:01). Five of 28 patients
(18%) had continuous oxygen therapy before LVRS, which
was unchanged after LVRS. Overall, 25 of 28 patients
(89%) reported a benefit after LVRS in terms of relief of
dyspnea and improvement of walking distance. Three
patients did not improve after LVRS; one of those patients
developed an ilio-femoral venous thrombosis after the right
heart catheterisation, one a bronchopleural fistula and asper-
gillus infection within the operated chest cavity, and one
had chronic productive bronchitis with Serratia marcescens
infection.
During the observation period, two patients (7%) under-
went LVRS on the contralateral side due to subsequent
deterioration after a period of subjective and objective
improvement following their first operation. Both suffered
from a-1-antitrypsin deficiency. One patient (heterozygote
phenotype) showed a decline of pulmonary function 5
months after the first operation and was subsequently oper-
ated on the contralateral side. Pulmonary function testing,
dyspnea and walking distance were improved 6 months after
the second intervention. The other patient (homozygote
phenotype) showed a modest improvement of symptoms
for only 3 months and underwent contralateral LVRS 18
weeks after the initial operation. Since the second operation
was without subjective and objective benefit, lung trans-
plantation had to be performed. All other patients revealed
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Fig. 1. FEV1 in patients before and after unilateral LVRS (mean ^ SD);
***P , 0:001.
Fig. 2. Residual volume in patients before and after unilateral LVRS
(mean ^ SD); *P , 0:05; **P , 0:01; ***P , 0:001.
Fig. 3. Assessment of dyspnea according to the modified BORG dyspnea
scale before and after unilateral LVRS (mean ^ SD); **P , 0:01;
***P , 0:001.
Fig. 4. Six-minute walking test before and after unilateral LVRS (mean ^
SD); *P , 0:05; ***P , 0:001.
subjective and objective improvement after unilateral
LVRS and denied the need for a contralateral intervention
during the 3 years observation period.
4. Discussion
This prospective study indicates that patients with severe,
disabling emphysema show a substantial and clinically rele-
vant benefit after unilateral LVRS. Both dyspnea and exer-
cise capacity improved significantly after unilateral LVRS
for at least 2 years. Only two patients had to be operated on
the contralateral side during the observation period, because
dyspnea and exercise capacity deteriorated to preoperative
levels. Both patients undergoing the second intervention had
suffered from a-1 antitrypsin deficiency.
To our knowledge, this is the first prospective study with
a systematic unilateral LVRS approach for patients with
diffuse emphysema, meaning that all patients fulfilling the
criteria for LVRS were treated unilaterally, without the
intention to treat the contralateral side sequentially after a
scheduled period of time [12].
At date, most authors consider the bilateral LVRS as the
procedure of choice, since the improvements of pulmonary
function are better after bilateral than unilateral LVRS
[3,5,6,13–15]. Our results suggest that patients with severe
emphysema fulfilling the criteria for LVRS show a signifi-
cant benefit after unilateral LVRS, in accordance with
recently published results from patients with unilateral
LVRS [16]. Unilateral LVRS resulted in a significantly
reduced RV in our patients up to 24 months postoperatively.
In addition, a significant improvement of FEV1 up to 3
months following unilateral LVRS was observed with a
mean gain of 177 ml. Kotloff and Brenner reported a similar
increase of FEV1 of 160 and 150 ml, respectively, after
unilateral LVRS [6,17]. Although the initial increase of
FEV1 is greater after the bilateral than the unilateral
approach, recent publications demonstrated that the initial
gain in FEV1 tends to decrease after time following LVRS,
with a correlation between the magnitude of short-term
improvement of FEV1 and the rate of annual postoperative
decline. Patients with unilateral LVRS showed a lower
annual decline as compared to bilateral LVRS (100 vs.
250 ml) [17]. These data indicate that a two stage, unilateral
procedure, in which a second, contralateral resection is
performed following significant deterioration in symptoms,
might be superior to a bilateral procedure in the long-term
follow-up. However, randomized, controlled studies need to
be performed to further study the two stage, unilateral
approach.
Our and other results suggest that pulmonary function
measurements do not necessarily correlate with the relief
of symptoms after LVRS. In our series, dyspnea was signifi-
cantly decreased up to 12 months and walking distance
significantly increased up to 2 years after the operation. Simi-
lar results were reported from bilateral LVRS [3,13,18]. An
important predictor regarding subjective assessment of the
results after LVRS seems to be steroid dependency. In our
series, daily steroid administration could be avoided in 13 out
of 22 patients at discharge following unilateral LVRS.
LVRS is considered by most authors as an entirely pallia-
tive approach in patients with diffuse emphysema, with the
goal to reduce dyspnea and improve quality of life
[4,9,19,20]. This goal should be achieved with the least
invasive and aggressive procedure in these fragile and
risky patients. Our results suggest that this goal might be
achieved by unilateral LVRS for at least 2 years. The
follow-up data 3 years after unilateral LVRS indicate that
the beneficial effect of LVRS is still present. However, these
data do not reach statistical significance, probably due to the
low patient number.
No 30-day-mortality was observed in our series, and the
perioperative morbidity was rather low, without need for
reintubation, prolonged ICU stay or tracheotomy, indicating
that unilateral LVRS is safe and well tolerated in patients
fulfilling the criteria for LVRS. Previously published trials
comparing unilateral and bilateral LVRS have documented
a higher incidence of postoperative mortality, re-intubation,
pneumonia and air leaks after bilateral than after unilateral
LVRS [6,21]. These data might further support the unilat-
eral approach, particularly in patients at high preoperative
risk, since the complication rate is lower in patients with
unilateral LVRS compared to bilateral LVRS.
During follow up, four out of 28 patients (14%) died at 3,
6, 12 and 16 months after surgery, respectively. Previous
reports investigating the mortality during follow-up after
unilateral or bilateral LVRS came to controversial conclu-
sions. Serna et al. showed a 2-year survival advantage after
bilateral LVRS as compared to unilateral LVRS, whereas
Naunheim et al. did not find a better survival after bilateral
than after unilateral LVRS [21,22]. However, caution in the
interpretation might be indicated since both studies were
retrospective.
Two patients were reoperated on the contralateral side
after a short-lasting benefit after unilateral LVRS, both of
them had a-1-antitryspin deficiency. Recent studies suggest
that patients with a-1-antitrypsin deficiency might not bene-
fit from LVRS, neither unilateral nor bilateral [7,13]. This
indicates that the necessity to perform LVRS on the contral-
ateral side was primarily related to poor patient selection
criteria than to the unilateral approach per se.
Overall, 25 of 28 patients (89%) reported a benefit after
unilateral LVRS over an observation period of up to 3 years.
The vast majority of the patients were satisfied with the
effects of the unilateral LVRS and did not need a second
intervention during the observation period. This indicates
that the palliative goal of the intervention can be reached
by the unilateral approach.
In summary, a substantial and clinically relevant benefit
can be achieved in patients with severe emphysema by
unilateral LVRS. However, relatively little data exist
about the long-term outcome of uni- and bilateral LVRS.
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Although bilateral LVRS appears to be superior to the
unilateral approach in the short term [14–16], the unilateral
approach may represent an effective and safe palliative
treatment, offering a substantial long-term benefit. Since
the published follow-up studies clearly indicate that lung
function is deteriorating over time after LVRS [15], we
assume that the unilateral approach might be a valuable
alternative to the bilateral procedure, because the unilateral
approach with the preservation of the non-operated side
offers the possibility of a further palliative intervention if
required. Larger prospective long-term follow-up studies
are required to define the optimal surgical procedure in
patients with severe emphysema.
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